Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination policies and migration. An estimated 257 million people are living with hepatitis B virus infection (defined as hepatitis B surface antigen positive). But there is still limited access to diagnosis and treatment of hepatitis Bin many resource-constrained settings. In 2015, of the 257 million people living with HBV infection, 9% (22 million) knew their diagnosis. Of those diagnosed, the global treatment coverage was only 8% ( 1.7 million). Many people are diagnosed only when they already have advanced liver disease. In May 2016, The World Health Assembly adopted the first “Global Health Sector Strategy on Viral Hepatitis, 2016-2020”. The strategy has a vision of eliminating

viral hepatitis as a public health problem antithesis encapsulated in the global targets of reducing new viral hepatitis infectionsby90%and reducing deaths due to viral hepatitisby65%by2030.

Sansure has developed Hepatitis B Viral DNA Quantitative Fluorescence Diagnostic Kit (fastHBV) with the foresight which agrees with WHO to provide patients living with HBV infection with an affordable, accessible and sustainable alternative to diagnose HBV, monitor disease progression, and assess the stage of  liver disease and eligibility for treatment